A detailed history of Blair William & CO transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Blair William & CO holds 9,215 shares of LGND stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,215
Previous 9,135 0.88%
Holding current value
$1.03 Million
Previous $769,000 20.03%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$82.7 - $110.11 $6,616 - $8,808
80 Added 0.88%
9,215 $923,000
Q2 2024

Aug 12, 2024

SELL
$68.53 - $87.91 $685 - $879
-10 Reduced 0.11%
9,135 $769,000
Q1 2024

May 09, 2024

SELL
$68.64 - $89.2 $755 - $981
-11 Reduced 0.12%
9,145 $668,000
Q4 2023

Feb 12, 2024

SELL
$49.57 - $72.63 $48,330 - $70,814
-975 Reduced 9.62%
9,156 $653,000
Q2 2023

Aug 11, 2023

SELL
$69.53 - $79.33 $6,605 - $7,536
-95 Reduced 0.93%
10,131 $730,000
Q1 2023

May 12, 2023

SELL
$65.67 - $77.08 $328 - $385
-5 Reduced 0.05%
10,226 $752,000
Q3 2022

Nov 09, 2022

SELL
$0.01 - $107.56 $0 - $3,226
-30 Reduced 0.29%
10,231 $881,000
Q2 2022

Aug 10, 2022

SELL
$74.52 - $117.06 $152,169 - $239,036
-2,042 Reduced 16.6%
10,261 $915,000
Q1 2022

May 13, 2022

SELL
$94.99 - $151.56 $258,182 - $411,940
-2,718 Reduced 18.09%
12,303 $1.38 Million
Q4 2021

Feb 14, 2022

BUY
$127.69 - $165.85 $13,279 - $17,248
104 Added 0.7%
15,021 $2.32 Million
Q3 2021

Nov 12, 2021

BUY
$102.33 - $144.73 $29,368 - $41,537
287 Added 1.96%
14,917 $2.08 Million
Q2 2021

Aug 12, 2021

SELL
$113.03 - $155.64 $1.62 Million - $2.23 Million
-14,325 Reduced 49.47%
14,630 $1.92 Million
Q1 2021

May 13, 2021

SELL
$99.52 - $215.83 $337,273 - $731,447
-3,389 Reduced 10.48%
28,955 $4.41 Million
Q4 2020

Feb 09, 2021

BUY
$80.55 - $106.05 $641,741 - $844,900
7,967 Added 32.68%
32,344 $3.22 Million
Q3 2020

Nov 06, 2020

BUY
$89.56 - $126.72 $259,276 - $366,854
2,895 Added 13.48%
24,377 $2.32 Million
Q2 2020

Aug 12, 2020

SELL
$68.28 - $123.65 $68,143 - $123,402
-998 Reduced 4.44%
21,482 $2.4 Million
Q1 2020

May 11, 2020

SELL
$63.37 - $107.88 $402,082 - $684,498
-6,345 Reduced 22.01%
22,480 $1.64 Million
Q4 2019

Feb 13, 2020

BUY
$96.94 - $113.59 $25,786 - $30,214
266 Added 0.93%
28,825 $3.01 Million
Q3 2019

Nov 12, 2019

SELL
$86.25 - $120.16 $4.43 Million - $6.17 Million
-51,309 Reduced 64.24%
28,559 $2.84 Million
Q2 2019

Aug 13, 2019

SELL
$107.38 - $129.34 $1.15 Million - $1.38 Million
-10,670 Reduced 11.79%
79,868 $9.12 Million
Q1 2019

May 14, 2019

SELL
$105.93 - $142.47 $5.84 Million - $7.86 Million
-55,155 Reduced 37.86%
90,538 $11.4 Million
Q4 2018

Feb 14, 2019

BUY
$128.36 - $272.13 $1.39 Million - $2.94 Million
10,801 Added 8.01%
145,693 $19.8 Million
Q3 2018

Nov 13, 2018

SELL
$211.18 - $274.49 $668,595 - $869,035
-3,166 Reduced 2.29%
134,892 $37 Million
Q2 2018

Aug 13, 2018

BUY
$150.77 - $207.98 $880,798 - $1.22 Million
5,842 Added 4.42%
138,058 $28.6 Million
Q1 2018

May 15, 2018

BUY
$138.63 - $182.62 $1.36 Million - $1.79 Million
9,812 Added 8.02%
132,216 $21.8 Million
Q4 2017

Feb 14, 2018

SELL
$128.36 - $147.04 $242,728 - $278,052
-1,891 Reduced 1.52%
122,404 $16.8 Million
Q3 2017

Nov 13, 2017

BUY
$120.91 - $137.94 $15 Million - $17.1 Million
124,295
124,295 $16.9 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.